Results of the epidemiological surveillance of diabetes mellitus in hospitals in Peru, 2012;Resultados de la vigilancia epidemiológica de diabetes mellitus en hospitales notificantes del Perú, 2012

Revista Peruana de Medicina Experimental y Salud Publica

Volumn 31, Issue 1, 2014, Pages 9-15

  Ramos, Willy ^a   López, Tania ^a   Revilla, Luis ^a   More, Luis ^b   Huamaní, María ^b   Pozo, Milagros ^c  

^a Perú   (Peru)

^b Instituto Nacional de Enfermedades Neoplásicas Dr Eduardo Cáceres Graziani   (Peru)

^c Hospital General de Huacho   (Peru)

Author keywords

Comorbidity (source: meSH NLM); Diabetes complications; Diabetes mellitus; Epidemiological surveillance; Risk factors

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

AGE; ARTICLE; BREAST CANCER; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DATA BASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH SURVEY; HOSPITAL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MICROALBUMINURIA; PATIENT COMPLIANCE; PERU; POSTMENOPAUSE; PROTEINURIA; SEX; TUBERCULOSIS; ADOLESCENT; ADULT; AGED; CHILD; EPIDEMIOLOGICAL MONITORING; MALE; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; EPIDEMIOLOGICAL MONITORING; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PERU; YOUNG ADULT;

EID: 84898406729     PISSN: 17264634     EISSN: 17264642     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Harris M, Zimmet P. Classification of diabetes mellitus and other categories of glucose intolerance. In: Alberti K, Zimmet P, R D, editors. International Texbook of Diabetes mellitus. 2nd ed. Chichester: John Wiley and sons Ltd.; 1997. p. 9 -23.
2. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20(7):1183-97.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995- 2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-31.
4. Gavin JR 3rd, Freeman JS, Shubrook JH, Lavernia F. Type 2 diabetes mellitus: practical approaches for primary care physicians. J Am Osteopath Assoc. 2011;111(5 suppl 4):S3-S12.
5. Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. In: Unwin N et al., editors. Diabetes Atlas. 4th ed. Brussels: International Diabetes Federation; 2009.
6. Rawal RB, Tapp RJ, Williams ED, Chan C, Yasin S, Oldenburg B. Prevention of type 2 diabetes and its complications in developing countries: a review. Int J Behav Med. 2012;19:121-33.
7. Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep. 2012;14(2):160-6. doi: 10.1007/ s11883-012-0227-2.
8. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet. 2008;371(9626):1800-9. doi: 10.1016/S0140-6736(08)60768-0.
9. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605.
10. Saito I. Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. Circ J. 2012;76(5):1066-73.
11. Kim JH, Kim DJ, Jang HC, Choi SH. Epidemiology of micro- and macrovascular complications of type 2 diabetes in Korea. Diabetes Metab J. 2011;35:571-7.
12. Instituto Nacional de Salud. Encuesta Nacional de Indicadores Nutricionales; Bioquímicos, Socioeconómicos y Culturales Relacionados a las Enfermedades Crónicas Degenerativas. Lima: Instituto Nacional de Salud; 2006.
13. Revilla L, Núñez E, Burga A, López T, Sánchez S, Zúñiga L, et al. Prevalencia de algunos factores de riesgo de enfermedades crónicas no transmisibles en el Perú, 2003-2006: Resultados preliminares. Bol Epidemiol. (Lima) 2009;18(Supl. 1):S3-S8.
14. Valdez W, Miranda J, Ramos W. Situación de la transición epidemiológica a nivel nacional y regional. Perú, 1990-2006. Rev Peru Epidemiol [Internet]. 2011 [citado el 12 de setiembre del 2013];15(3)[5pp.]. Disponible en: http://sisbib.unmsm. edu.pe/bvrevistas/epidemiologia/v15_ n3/pdf/a03v15n3.pdf
15. Valdez-Huarcaya W, Miranda J, Ramos W, Martínez C, Mariños C, Napanga O, et al. Estimación de la carga de enfermedad por muerte prematura y discapacidad en el Perú. Año 2008. Rev Peru Epidemiol [Internet]. 2012 [citado el 12 de setiembre del 2013];1(2):[9 pp.]. Disponible en: http://rpe.epiredperu.net/rpe_ediciones/2012_V16_N02/5AO_Vol16_No2_2012_Carga_enfermedad_discapacidad.pdf
16. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care. 1987;10(1):1-19.
17. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
18. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-17.
19. American Diabetes Association. Standards of Medical Care in Diabetes-2011. Diabetes Care. 2011;34:S11-S61.
20. American Association of Clinical Endocrinologists Board of Directors; American College of Endocrinologists Board of Trustees. American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract. 2010;16(2):155-6.
21. Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2005;28(11):2780-6.
22. Sudo N, Yoshiike N. Effects of health education on the glycemic control of type 2 diabetic patients: a meta-analysis. Jpn J Nutr Diet. 2006;64(6):309-24.
23. Rose BD, McCulloch DK. Microalbuminuria en la nefropatía diabética. Rev Cubana Med. 2000;39(1):57-65.
24. Chen H, Zheng Z, Huang Y, Guo K, Lu J, Zhang L, et al. A Microalbuminuria Threshold to Predict the Risk for the Development of Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients. PLoS ONE. 2012;7(5):e36718.
25. Maniavat MR, Afkmami M, Shoja MR. Retinopathy and microalbuminuria in type II diabetic patients. BMC Ophtalmol. 2004;4:9.
26. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002;39(3):445-59.
27. Schroner Z, Lazurova I, Petrovicova J. Autoimmune thyroid diseases in patients with diabetes mellitus. Bratisl Lek Listy. 2008;109(3):125-9.
28. Sullivan T, Ben Amor Y. The Co-Management of Tuberculosis and Diabetes: Challenges and Opportunities in the Developing World. PLoS Med. 2012;9(7):e1001269.
29. Giovanucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and Cancer. Diabetes Care. 2010;33:1674-85.
30. Liao S, Li J, Wei W, Wang L, Zhang Y, Li J, et al. Association between Diabetes Mellitus and Breast Cancer Risk: a Meta-analysis of the Literature. Asian Pacific J Cancer Prev. 2011;12:1061-5.